x
African Health Sciences
[contact-form-7 id="2459" title="Sidebar Form"]

  • 256(41)530021
  • info@africanhealthsciences.org
African Health Sciences
  • info@africanhealthsciences.org
  • Give Feedback
  • Home
  • About Us
  • Staff
  • Focus & Scope
  • For Authors
  • More Links
    • About The Journal
    • Latest Articles
    • Journal Archives
    • Our Events
    • Faq’s
  • Contact Us
Logo

Contact Info

  • P. O. Box 7072 Kampala, Uganda
  • +256(41)530021
  • info@africanhealthsciences.org
  • ISSN 1680-6905
  • <!--
  • -->

09Sep2017

Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients.

by admin,  0 Comments

Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients.

Yousri Mostafa Hussein, Ayman Alhazmi, Saad Alzahrani, Ahmad El-Askary1,, Abdulrahman Alghamdy5
, Eman Bayomy4, Assmaa Selim, Mohammed Alghamdy.

1. Medical Laboratories Department, Faculty of Applied Medical Sciences, Taif University, Saudi Arabia
2. Medical Biochemistry Department, Faculty of Medicine, Zagazig University, Egypt
3. Community Medicine Department, Faculty of Medicine, Taif University, Saudi Arabia
4. Medical Biochemistry Department, Damietta Faculty of Medicine, Al-Azhar University, Egypt
5. Community medicine, Faculty of Applied Medical Sciences, Taif University, Saudi Arabia
6. Histology and Cell Biology Departement, Faculty of Medicine, Zagazig University

Abstract:

Background: Many recent studies support the idea that osteopontin (OPN) can be used to predict the success of pegylated interferon (PEG IFN) alpha-2b/ribavirin therapy in chronic HCV patients.
Objective: Our aim was to investigate the role of plasma OPN and its gene polymorphism at nt – 443 in response to PEG IFN in Saudi patients with chronic HCV.
Methods:Blood was collected from 87 patients with chronic hepatitis C before treatment, then patients received PEG IFN α2b plus ribavirin combination therapy. Another 25 healthy subjects, matched for age and sex to patients, were enrolled as controls. Single nucleotide polymorphism (SNP) in OPN at nt – 443 and its blood level were analyzed.
Results: The frequency of patients who reached sustained virological response (SVR) was increased in patients with T/T at nt – 443 than in those with C/C or C/T. Also the frequency of T allele was increased in responders than in non-responders. However, this increase was not statistically significant. The blood level of OPN was significantly increased in non-responders (Mean±SD=37.21±3.9) in comparison to responders (Mean±SD=33.22±4.1).
Conclusion:Osteopontin blood level can be considered as a reliable predictor to PEG IFN α2b plus ribavirin therapy in chronic HCV Saudi Patients.
Keywords: OPN, PEG IFN, HCV, SVR, SNP, RT-PCR.

Related posts:

Diagnosis and treatment of unconsummated marriage in an Iranian couple.

Intestinal candidiasis and antibiotic usage

Role of offending out-door aero-allergen

Recent Posts

  • Editor’s choice: Tackling infectious diseases, NCDs and sexual reproductivehealth issues as we enter our 24th year of remarkable growth
  • Preconception and contraceptive care for women living with HIV/AIDSattending antiretroviral treatment clinics in Lagos State, Nigeria
  • Effects of SNPs on TNF-α and IL-10 cytokine expression in TB and HIVpatients in the Capricorn district, Limpopo Province, South Africa
  • Prevalence of Schistosomiasis in a neglected community, South western Nigeria at two points in time, spaced three years apart
  • Review of Leishmaniasis in the Middle East and North Africa

Recent Comments

No comments to show.

Archives

  • April 2024
  • May 2019
  • April 2019
  • September 2018
  • August 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017

Categories

  • 2001 Issues
  • 2002 Issues
  • 2003 Issues
  • 2004 Issues
  • 2005 Issues
  • 2006 Issues
  • 2007 Issues
  • 2008 Issues
  • 2009 Issues
  • 2010 Issues
  • 2011 Issues
  • 2012 Issues
  • 2013 Issues
  • 2014 Issues
  • 2015 Issues
  • 2016 Issues
  • 2017 Issues
  • 2018 Issues
  • 2019 Issues
  • 2024 Issues
  • Articles
  • December issue
  • December Release
  • June Issue
  • June Release
  • March Issue
  • March Issue
  • March Release
  • News
  • number / volume 2
  • number /volume 1
  • number /volume 1
  • number /volume 1 2008
  • number 1
  • number 1
  • number 1
  • number 1
  • number 1
  • number 1
  • number 1
  • number 2
  • number 2
  • number 2
  • number 2
  • number 2
  • number 2
  • number 2
  • number 2 special Issue
  • number 2 special Issue 2
  • number 3
  • number 3
  • number 3
  • number 3
  • number 3
  • number 3
  • number 3
  • number 4
  • number 4
  • number 4
  • number 4
  • number 4
  • number 4
  • number/ volume 3 2008
  • number/ volume 4 2008
  • number/volume 1
  • number/volume 1
  • number/volume 2
  • number/volume 2
  • number/volume 2 2008
  • number/volume 3
  • number/volume 3
  • number/volume 3
  • number/volume 4
  • number/volume1
  • September Issue
  • September Release
  • Special Edition
  • special Issue
  • Uncategorized
  • Vol. 24 No. 1 (2024)
  • volume 1
  • volume 1
  • volume 1
  • volume 2
  • volume 2
  • volume 2
  • volume 2
  • volume 2
  • volume 3
  • volume 3
  • volume 3
  • volume 3
  • volume 4
  • volume 4
  • volume 4
  • volume 4
  • volume1

Categories

  • 2001 Issues
  • 2002 Issues
  • 2003 Issues
  • 2004 Issues
  • 2005 Issues
  • 2006 Issues
  • 2007 Issues
  • 2008 Issues
  • 2009 Issues
  • 2010 Issues
  • 2011 Issues
  • 2012 Issues
  • 2013 Issues
  • 2014 Issues
  • 2015 Issues
  • 2016 Issues
  • 2017 Issues
  • 2018 Issues
  • 2019 Issues
  • 2024 Issues
  • Articles
  • December issue
  • December Release
  • June Issue
  • June Release
  • March Issue
  • March Issue
  • March Release
  • News
  • number / volume 2
  • number /volume 1
  • number /volume 1
  • number /volume 1 2008
  • number 1
  • number 1
  • number 1
  • number 1
  • number 1
  • number 1
  • number 1
  • number 2
  • number 2
  • number 2
  • number 2
  • number 2
  • number 2
  • number 2
  • number 2 special Issue
  • number 2 special Issue 2
  • number 3
  • number 3
  • number 3
  • number 3
  • number 3
  • number 3
  • number 3
  • number 4
  • number 4
  • number 4
  • number 4
  • number 4
  • number 4
  • number/ volume 3 2008
  • number/ volume 4 2008
  • number/volume 1
  • number/volume 1
  • number/volume 2
  • number/volume 2
  • number/volume 2 2008
  • number/volume 3
  • number/volume 3
  • number/volume 3
  • number/volume 4
  • number/volume1
  • September Issue
  • September Release
  • Special Edition
  • special Issue
  • Uncategorized
  • Vol. 24 No. 1 (2024)
  • volume 1
  • volume 1
  • volume 1
  • volume 2
  • volume 2
  • volume 2
  • volume 2
  • volume 2
  • volume 3
  • volume 3
  • volume 3
  • volume 3
  • volume 4
  • volume 4
  • volume 4
  • volume 4
  • volume1

Archives

  • April 2024
  • May 2019
  • April 2019
  • September 2018
  • August 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017

Tags

Achives Latest News


ISSN 1680-6905

  • P. O. Box 7072 ,Kampala, Uganda
  • Call Us: 256(41)530021
  • info@africanhealthsciences.org

Latest Activities

Usefull Link

  • About AHS
  • Services
  • Focus & Scope
  • Our Articles
  • Contact Us

Subscribe

For research updates from African Health Sciences, sign up now!

[contact-form-7 id="1620" title="Subscribe"]

African Health Sciences © All Right Reserved